Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Continued Examination Under 37 CFR 1.114
A request for continued examination under 37 CFR 1.114 ("RCE"), including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on May 18, 2026, has been entered.
Status of Claims
Claims 1-20 were previously pending and subject to a Final Office Action having a notification date of February 24, 2026 (“Final Office Action”). Following the Final Office Action, Applicant filed the RCE and an amendment on May 18, 2026 (“Amendment”), amending claims 1, 7, 8, 12, 16, 19, and 20 and adding new claim 21-23.
The present non-final Office Action addresses pending claims 1-23 in the Amendment.
Response to Arguments
Response to Applicant’s Arguments Regarding Double Patenting Claim Rejections
In response to Applicant’s request to hold the double patenting rejection in abeyance without filing a Terminal Disclaimer until allowable subject matter is identified by the Patent Office, the filing of a Terminal Disclaimer should not be held in abeyance as doing so is necessary for further consideration of the rejection of the claims. MPEP §804. Therefore, the double patenting rejections are maintained.
Response to Applicant’s Arguments Regarding Claim Rejections Under 35 USC §101
In relation to the claim rejections under 35 USC 101 set forth in the non-final Office Action, these rejections are now withdrawn when currently pending claims 1-23 are considered in view of the 2019 Revised Patent Subject Matter Eligibility Guidance (which collectively includes the guidance in the January 7, 2019 Federal Register notice and the October 2019 update issued by the USPTO as incorporated into the MPEP) and Applicant' s remarks in the Amendment.
While independent claims 1, 19, and 20 recite a method of organizing human activity because they facilitate sharing patient data with a healthcare clinic which relates to managing interactions between people and/or a mental process because they include steps that can be practically performed in the human mind (e.g., authenticating the clinic, receiving the request, obtaining the patient confirmation, determining that the clinic is authorized to receive access to the patient data, etc.), the claims recite additional limitations that amount to a “practical application” of the abstract idea and/or are “significantly more” than the abstract idea. For instance, at least the additional limitations of capturing a computer readable code including clinic identifying and authentication information using an image capture component of a mobile device associated with a patient; authenticating the clinic identifying information of the healthcare clinic extracted from the computer readable code with a health information provider by transmitting the authentication information extracted from the computer readable code; displaying the authenticated clinic identifying information to the patient via the mobile device for confirmation to share the patient data with the healthcare clinic upon receiving an authentication indication of the healthcare clinic from the health information provider; and transmitting the patient data, over a communication channel, to the healthcare clinic based on determining that the healthcare clinic is authorized to receive access to the patient data improve technology by advantageously enabling a patient to more efficiently, securely, and privately share the patient’s health data with a healthcare clinic/practitioner in a manner that avoids manual identification of the healthcare clinic/practitioner and the attendant errors and inefficiencies that can arise therewith ([0020]-[0026] of the present specification). MPEP 2106.05(a).
Furthermore, the above-discussed additional limitations amount to other meaningful limitations beyond generally linking the use of the judicial exception to a particular technological environment. MPEP 2106.05(e). Specifically, such limitations are meaningful “because they integrate the results of the analysis into a specific and tangible method that results in the method moving form abstract scientific principles to specific application.” Id.
Response to Applicant’s Arguments Regarding Claim Rejections Under 35 USC §103
These rejections are withdrawn in view of the Amendment.
Claim Objections
Claims 1, 4-6, 7, 9, 10, 12, 19, and 20 are objected to because of the following informalities:
-In claim 1, lines 8-9, it appears that "transmitting the authentication information extracted from the computer readable code" should be changed to -- transmitting the authentication information extracted from the computer readable code to the health information provider--.
-In claim 1, line 20, it appears that "authentication" should be changed to --the authentication--.
-In claim 4, lines 1-3, it appears that "wherein the computer-readable code comprises: an authentication code provided to a healthcare clinic" should be changed to -- wherein the authentication information
lines 3-4, it appears that ", and clinic identifying information for the healthcare clinic" should be removed because it was already recited in claim 1.
-It appears that claim 5 should be canceled because claim 1 already recites that the authentication information (which includes an authentication code per claim 4) and the clinic identifying information are extracted from the computer readable code.
-It appears that claim 6 should depend from claim 4.
-In claim 6, line 2, it appears that "extracting the authentication code" should be changed to --extracting the authentication information--.
Appropriate correction is required.
-It appears that claim 7 should depend from claim 4.
-In claim 7, lines 4-6, it appears that "wherein authenticating…exists on a list" should be deleted because it is already recited in this claim.
-It appears that claim 9 should depend from claim 4.
-In claim 9, line 2, it appears that "authentication code" should be changed to --authentication information--. -In claim 9, line 5, it appears that "authentication code" should be changed to --authentication information--. -It appears that claim 10 should be canceled because claim 1 already recites these limitations.
-It appears that lines 2-3 of claim 12 should be deleted because claim 1 already recites these limitations.
-Claims 19 and 20 should be amended in a manner similar to claim 1.
Appropriate correction is required.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1-23 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-12, 14, 15, 17, and 18 of U.S. Patent No. 12,158,971 ("the '971 Patent"). Although the claims at issue are not identical, they are not patentably distinct from each other:
For reference, a claim chart comparing independent claim 1 of the present application to claim 1 of the '971 Patent is presented below:
Independent Claim 1 of the Present Application
Independent Claim 1 of the '971 Patent
A method for securely sharing patient data, comprising:
A method for securely sharing patient data, comprising:
capturing a computer readable code using an image capture component of a mobile device associated with a patient, the computer readable code associated with a healthcare clinic, wherein the computer readable code includes clinic identifying information for the healthcare clinic;
capturing a computer-readable code using an image capture component of a mobile device associated with a patient, the computer-readable code comprising an authentication code provided to a healthcare clinic and clinic identifying information for the healthcare clinic; extracting the authentication code and the clinic identifying information from the computer-readable code, wherein: the authentication code is extracted by decrypting the authentication code, and the clinic identifying information is extracted by decrypting the clinic identifying information of the computer-readable code based on the authentication code;
in response to capturing the computer readable code, authenticating the clinic identifying information of the healthcare clinic extracted from the computer readable code with a health information provider by transmitting the authentication information extracted from the computer readable code;
authenticating the healthcare clinic with a health information provider based on the authentication code and the clinic identifying information;
in response to receiving an authentication indication of the healthcare clinic from the health information provider, displaying the authenticated clinic identifying information to the patient via the mobile device for confirmation to share the patient data with the authenticated healthcare clinic;
upon authenticating the healthcare clinic with the health information provider, displaying the clinic identifying information to the patient via the mobile device for confirmation to share the patient data with the healthcare clinic;
obtaining, from the patient, a confirmation to share the patient data with the healthcare clinic based on the displayed clinic identifying information
[[the second to last limitation below recites "the confirmation to share the patient data" which corresponds to the above-recited clinic identifying information displayed to the patient - therefore, the confirmation to share the patient data with the clinic based on the displayed clinic identifying information is obtained from the patient]]
receiving a request from the healthcare clinic to provide the healthcare clinic with access to the patient data;
receiving a request from the healthcare clinic to provide the healthcare clinic with access to the patient data;
determining that the healthcare clinic is authorized to receive access to the patient data based on (I) authentication of the healthcare clinic and (II) the confirmation obtained from the patient; and
determining that the healthcare clinic is authorized to receive access to the patient data based on authentication of the healthcare clinic, authentication of the patient, and the confirmation to share the patient data with the healthcare clinic from the patient; and
transmitting the patient data, over a communication channel, to the healthcare clinic based on determining that the healthcare clinic is authorized to receive access to the patient data.
transmitting the patient data, over a communication channel, to the healthcare clinic based on determining that the healthcare clinic is authorized to receive access to the patient data.
Furthermore, a claim chart indicating which claims of the '971 Patent recite corresponding limitations of the remaining present claims is presented below:
Present Application
'971 Patent
Claim 2
Claim 2
Claim 3
Claim 3
Claim 4
Claim 1
Claim 5
Claim 1
Claim 6
Claim 1
Claim 7
Claim 4
Claim 8
Claim 5
Claim 9
Claim 11
Claim 10
Claim 1
Claim 11
Claim 6
Claim 12
Claim 7
Claim 13
Claim 8
Claim 14
Claim 9
Claim 15
Claim 10
Claim 16
Claim 12
Claim 17
Claim 14
Claim 18
Claim 15
Claim 19
Claim 17
Claim 20
Claim 18
Claim 21
Claim 1
Claim 22
Claim 2
Claim 23
Claim 1
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to JONATHON A. SZUMNY whose telephone number is (303) 297-4376. The examiner can normally be reached Monday-Friday 7-5.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jason Dunham, can be reached on 571-272-8109. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/JONATHON A. SZUMNY/Primary Examiner, Art Unit 3686